Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Declines By 65.9%

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a significant drop in short interest in September. As of September 15th, there was short interest totalling 35,900 shares, a drop of 65.9% from the August 31st total of 105,400 shares. Approximately 2.6% of the company’s shares are sold short. Based on an average daily volume of 1,330,000 shares, the days-to-cover ratio is currently 0.0 days.

Windtree Therapeutics Price Performance

Shares of WINT stock opened at $3.26 on Wednesday. The business’s 50-day moving average price is $6.93 and its 200-day moving average price is $5.57. Windtree Therapeutics has a 12 month low of $2.75 and a 12 month high of $27.00.

Windtree Therapeutics (NASDAQ:WINT) last announced its quarterly earnings results on Monday, August 19th. The company reported ($20.91) EPS for the quarter, missing analysts’ consensus estimates of ($8.11) by ($12.80). Analysts predict that Windtree Therapeutics will post -2.38 earnings per share for the current year.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.